IL2 and graft versus host disease: Pre-clinical evidence from a xenogeneic model showed that an in vitro IL-2-activated human NK cell infusion promoted GVHD in SCID mice via the production of cytokines such as IFN-γ and tumor necrosis factor-α (TNF-α) (111, 112).